Radius Health Forecasted to Post FY2018 Earnings of ($4.81) Per Share (RDUS)

Radius Health (NASDAQ:RDUS) – Research analysts at Cantor Fitzgerald issued their FY2018 EPS estimates for Radius Health in a report issued on Tuesday, May 22nd. Cantor Fitzgerald analyst M. Goldstein forecasts that the biopharmaceutical company will post earnings of ($4.81) per share for the year. Cantor Fitzgerald has a “Buy” rating and a $58.00 price target on the stock. Cantor Fitzgerald also issued estimates for Radius Health’s FY2019 earnings at ($3.12) EPS.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.46) by $0.09. The business had revenue of $14.50 million for the quarter, compared to the consensus estimate of $13.80 million. Radius Health had a negative return on equity of 108.95% and a negative net margin of 706.11%. During the same quarter in the prior year, the business posted ($1.32) earnings per share.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley increased their price target on Radius Health from $57.00 to $61.00 and gave the stock an “overweight” rating in a research report on Friday, March 2nd. BidaskClub downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. ValuEngine raised Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Leerink Swann assumed coverage on Radius Health in a research report on Thursday, March 29th. They set an “outperform” rating and a $53.00 price target on the stock. Finally, Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Three analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $50.89.

Shares of NASDAQ:RDUS opened at $28.91 on Thursday. The company has a market cap of $1.32 billion, a P/E ratio of -4.98 and a beta of 1.27. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16. The company has a debt-to-equity ratio of 0.87, a quick ratio of 6.41 and a current ratio of 6.55.

In other Radius Health news, major shareholder Growth N. V. Biotech bought 60,000 shares of Radius Health stock in a transaction on Monday, May 21st. The shares were purchased at an average price of $29.27 per share, with a total value of $1,756,200.00. Following the acquisition, the insider now owns 6,110,913 shares in the company, valued at approximately $178,866,423.51. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Growth N. V. Biotech bought 80,000 shares of Radius Health stock in a transaction on Friday, March 2nd. The stock was acquired at an average cost of $32.52 per share, for a total transaction of $2,601,600.00. Following the acquisition, the insider now owns 5,853,799 shares in the company, valued at approximately $190,365,543.48. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 230,000 shares of company stock worth $7,538,800. Company insiders own 3.42% of the company’s stock.

Several hedge funds have recently modified their holdings of RDUS. Consonance Capital Management LP acquired a new stake in shares of Radius Health in the 4th quarter valued at $84,168,000. OppenheimerFunds Inc. acquired a new stake in shares of Radius Health during the 1st quarter valued at $29,903,000. TimesSquare Capital Management LLC boosted its holdings in shares of Radius Health by 16.2% during the 4th quarter. TimesSquare Capital Management LLC now owns 1,871,445 shares of the biopharmaceutical company’s stock valued at $59,456,000 after acquiring an additional 261,080 shares in the last quarter. Eversept Partners LLC acquired a new stake in shares of Radius Health during the 4th quarter valued at $6,179,000. Finally, BB Biotech AG boosted its holdings in shares of Radius Health by 2.7% during the 1st quarter. BB Biotech AG now owns 5,853,799 shares of the biopharmaceutical company’s stock valued at $210,386,000 after acquiring an additional 155,000 shares in the last quarter.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply